MicroConstants Q3 Company Newsletter – July 2017
On October 11, 2017
On October 24, 2017
On November 12-15, 2017
Enhancing Sensitivity of Biomarkers in MSD and ELISA Using Immunocapture
Biomarkers are extremely important for disease diagnosis and identifying therapeutic responses in specific patient populations. They also assist in detecting toxicities and monitoring efficacy of drugs. The use of biomarkers in the profiling of tumors for targeted treatments has also shown great promise in cancer treatment. Thus, biomarker research has become an integral part of the drug discovery and development process. One hurdle that we face when developing assays to measure biomarkers is that the immunoassay is not sensitive enough to detect the biomarker at its endogenous concentration. Our immunology group here at MicroConstants set out to evaluate an immunocapture product from ThermoFisher Scientific as a potential solution.
MicroConstants is evaluating Thermo Scientific Mass Spectrometric Immunoassay (MSIA) technology as a potential solution for use in immunoassays. Eluates are destined for LCMS mostly, but we are using the technology to get enhanced sensitivity for biomarkers in ELISA or MSD analysis of the eluates. The proprietary microcolumns are streptavidin coupled, so that a solution of biotinylated antibody can be applied to give specificity. The analyte of interest is then captured onto the column, which is then eluted with acid to retrieve the analyte in a small volume. Small and large molecular drugs are currently being processed with this technology to yield greater selectivity and sensitivity in their respective bioanalyses.
Laboratory Equipment Upgrades
MicroConstants strives to provide excellent service through equipment upgrades. As a result, MicroConstants recently purchased several high capacity and performance, 5920 R Eppendorf centrifuges. Adding this equipment to our laboratories will help us be more efficient when processing your precious samples.
Caco-2 Permeability Studies
The Caco-2 system is recognized as a predictive model which can help predict human intestinal absorption and oral bioavailability. We use 24-well plates with seeded and differentiated (21-days) Caco-2 cells to assess the apparent permeability of the test article across the intestinal barrier. By determining both the apical to basolateral (A-B) and the basolateral to apical (B A) permeability, the efflux ratio can be calculated. Additionally, inhibition of the P glycoprotein transporter can help determine if the test article is a P-gp substrate.